Cardinal Health(US:CAH)2026-02-05 13:47Revenue and Earnings Growth - Revenue for the three and six months ended December 31, 2025 increased 19% to $65.6 billion and 21% to $129.6 billion, respectively, primarily due to branded and specialty pharmaceutical sales growth[12]. - GAAP operating earnings for the three and six months ended December 31, 2025 increased 29% to $707 million and 23% to $1.4 billion, respectively, driven by acquisitions and increased contributions from pharmaceutical products[14]. - Non-GAAP operating earnings for the same periods increased 38% to $877 million and $1.7 billion, respectively, due to similar factors impacting GAAP earnings[15]. - GAAP diluted EPS for the three and six months ended December 31, 2025 increased 19% to $1.97 and 15% to $3.85, respectively[17]. - Non-GAAP diluted EPS for the same periods increased 36% to $2.63 and $5.18, respectively[18]. Acquisitions - The acquisition of Solaris Health for approximately $1.9 billion was completed on November 3, 2025, enhancing the company's MSO platform[19]. - Solaris Health includes over 750 providers across more than 250 practice locations in 14 states, contributing to the Pharma segment[20]. - The acquisition of Advanced Diabetes Supply Group (ADS) was finalized for about $1.0 billion, with integration costs of $7 million reported for the same period[126][127]. - The company acquired a 73% ownership interest in GI Alliance for approximately $2.8 billion, with a call right to purchase the remaining interests starting three years post-acquisition[128]. - The total identifiable net assets acquired from Solaris Health, Urology America, ADS, GIA, and ION amounted to $2,140 million, with goodwill recognized at $6,784 million across these acquisitions[133]. Segment Performance - Pharmaceutical and Specialty Solutions segment revenue increased 19% to $60.7 billion for the three months ended December 31, 2025, and 21% to $119.9 billion for the six months ended December 31, 2025, driven by growth in branded and specialty pharmaceutical sales[31]. - Global Medical Products and Distribution segment revenue rose 3% to $3.3 billion for the three months ended December 31, 2025, and $6.4 billion for the six months ended December 31, 2025, primarily due to volume growth from existing customers[32]. - Other segment revenue surged 34% to $1.7 billion for the three months ended December 31, 2025, and 36% to $3.4 billion for the six months ended December 31, 2025, attributed to growth in at-Home Solutions and the acquisition of ADS[33]. Financial Position and Cash Flow - Cash and equivalents balance was $2.8 billion at December 31, 2025, down from $3.9 billion at June 30, 2025, with net cash provided by operating activities at $1.7 billion[54]. - Total long-term obligations, including current portion and other short-term borrowings, amounted to $9.0 billion at December 31, 2025, up from $8.5 billion at June 30, 2025[61]. - Cash flows from operating activities provided $1,659 million, a significant recovery compared to a cash outflow of $2,043 million in the prior year[107]. - The company reported a net cash used in investing activities of $2,122 million, compared to $1,064 million in the prior year[107]. Expenses and Costs - SG&A expenses increased 15% to $1.5 billion for the three months ended December 31, 2025, and $3.0 billion for the six months ended December 31, 2025, primarily due to acquisitions[36]. - Interest expense, net increased significantly to $88 million for the three months ended December 31, 2025, and $168 million for the six months ended December 31, 2025, due to additional debt financing for recent acquisitions[51]. - The company incurred $130 million in amortization and other acquisition-related costs for the three months ended December 31, 2025[100]. Tax and Legal Matters - The effective tax rate was 25.2% for the three months ended December 31, 2025, compared to 21.4% for the same period in 2024[52]. - As of December 31, 2025, the company accrued $4.3 billion related to national opioid litigation settlements, with expected payments continuing through 2038[64]. - The IRS has proposed an adjustment that could result in an additional federal income tax liability of approximately $160 million, plus interest, related to a restructuring from a 2017 acquisition[183]. - The company has paid approximately $2.2 billion to settling governmental entities under the National Opioid Settlement Agreement and expects to pay up to an additional $4.1 billion through 2038[170]. Shareholder Returns - The company approved quarterly dividends of $0.5107 per share, amounting to an annualized total of $2.04 per share, with payments made on specified dates[66]. - During the six months ended December 31, 2025, the company repurchased $750 million of its common shares under accelerated share repurchase programs[67]. - The company has a remaining $2.0 billion authorized for share repurchases under its $3.5 billion program, which is set to expire on December 31, 2027[99]. Inventory and Assets - Current assets increased to $39,230 million as of December 31, 2025, compared to $36,373 million as of June 30, 2025, representing an increase of 5.1%[104]. - Inventories, net, rose to $20,116 million as of December 31, 2025, compared to $16,831 million as of June 30, 2025, marking a significant increase of 19.0%[104]. - Total assets increased to $58,083 million as of December 31, 2025, compared to $53,122 million as of June 30, 2025, reflecting a growth of 9.4%[104]. Goodwill and Intangible Assets - Goodwill increased to $11,609 million as of December 31, 2025, primarily due to the Solaris acquisition, reflecting expected growth and synergies[142]. - The total identifiable intangible assets acquired amounted to $1,104 million, with customer intangibles making up a significant portion of this value[133]. - The estimated fair value of customer intangibles for ADS was determined to be $472 million, utilizing a multi-period excess earnings method[136]. Compliance and Investigations - The company is cooperating with a Department of Justice investigation regarding potential violations of the Anti-Kickback Statute and False Claims Act[178]. - The company has settled approximately 4,375 claims related to IVC filter product liability for $275 million, with payments expected to continue as additional plaintiffs meet procedural requirements[180].